An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
A small randomized crossover study in eight adults with type 1 diabetes on automated insulin delivery found that splitting isomaltulose into smaller servings during exercise produced steadier plasma glucose than a single pre-exercise serving. PICO summary and expert commentary.
A 12-week four-arm randomised trial in 36 male recreational athletes found that combined diet plus exercise improved body composition and glycaemic markers, with small effect sizes. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.
A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
A first-in-human phase 1 trial of oral amycretin in overweight or obesity found it safe and tolerable, with dose-dependent gastrointestinal effects and exploratory weight loss. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
A secondary analysis of a metformin-versus-insulin gestational diabetes trial found cord serum lipids associated with offspring beta-cell function at age nine. PICO summary and expert commentary.
A secondary analysis of a weight-loss-maintenance RCT found that low-calorie-diet weight loss raised serum 25(OH)D in both sexes, but further loss and low baseline vitamin D tracked with maintenance only in women. PICO summary and expert commentary.
A secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial finds tirzepatide improved health-related quality of life versus placebo in adults with obesity, with larger gains at greater weight loss. PICO summary and expert commentary.